USP17L17
associated omics dataQ-omics provides the consensus-scored USP17L17 profile across patient tissues and cancer cell-line models. USP17L17 expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in BRCA.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP17L17 — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes USP17L17 survival associations across molecular data types. USP17L17 RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP17L17 RNA expression–survival associations across cancer types. High USP17L17 expression shows unfavorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for USP17L17 RNA expression.
Cross-omics associations
This table shows molecular features associated with USP17L17 in patient tissues and cancer cell lines. In cancer cell lines, USP17L17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN.